Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and

You are here:  Home >>  News >>  Research & Development >>  Exact therapy for rare genetic disorders of obesity

Exact therapy for rare genetic disorders of obesity

January 12, 2018 By biospectrumasia

WuXi NextCODE, the emerging global standard platform for genomic data, announced a partnership with Rhythm Pharmaceuticals, a biopharmaceutical company.

Partnership focused on developing and commercializing therapies for the treatment of rare genetic disorders of obesity, under which Rhythm is applying WuXi NextCODE's proprietary deep learning capabilities to identify key genetic markers for rare metabolic syndromes.

The goal is to use that information to optimize the development of Rhythm's investigational compounds.

The first phase of the partnership involved mining WuXi NextCODE's knowledgebase of all major reference datasets to identify all rare sequence variants in the POMC, PCSK1, and LEPR genes in the MC4R pathway.

This is a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite.

WuXi NextCODE's advanced artificial intelligence (AI) laboratory then applied its proprietary Deep CODESM algorithm to score the variants for their predictive impact on obesity.

Add a comment
Click here to Login or to Register for free. You will be taken back to your selected item after Login/Registration.
More>> MarketNews
More>> Editors’Picks
More>> TopStories
More>> HotTags
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
live chat